TNG Transgene SA

Availability of Transgene’s Half-Year Financial Report as of June 30, 2025

Availability of Transgene’s Half-Year Financial Report as of June 30, 2025

TRANSGENE (Paris: TNG) today announced that it has made available to the public and filed with the Autorité des marchés financiers its half-year financial report as of June 30, 2025.

The document is available on the Company’s website: , in the “Investors/Financial information” section.

This report comprises the following documents:

  • 2025 half-year financial statements;
  • Half-year management report;
  • Statutory Auditors’ report on the 2025 half-year financial statements;
  • Declaration by the person responsible for this half-year financial report.

Contacts

Media: 



Caroline Tosch 

Corporate and Scientific Communications Manager 

+33 3 68 33 27 38 

  
 
Investors & Analysts: 
Nadège Bartoli 

Investor Relations Analyst and Financial Communication Officer

+33 3 88 27 91 03 
Lucie Larguier 

Chief Financial Officer

+33 3 88 27 91 00 

 

Attachment



EN
16/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Transgene SA

 PRESS RELEASE

Availability of Transgene’s Half-Year Financial Report as of June 30, ...

Availability of Transgene’s Half-Year Financial Report as of June 30, 2025 TRANSGENE (Paris: TNG) today announced that it has made available to the public and filed with the Autorité des marchés financiers its half-year financial report as of June 30, 2025. The document is available on the Company’s website: , in the “Investors/Financial information” section. This report comprises the following documents: 2025 half-year financial statements;Half-year management report;Statutory Auditors’ report on the 2025 half-year financial statements;Declaration by the person responsible for this hal...

 PRESS RELEASE

2025 Half-year financial information

2025 Half-year financial information 2025 Half-year financial information Attachment

 PRESS RELEASE

RAPPORT SEMESTRIEL 2025

RAPPORT SEMESTRIEL 2025 RAPPORT SEMESTRIEL 2025 Pièce jointe

 PRESS RELEASE

Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG405...

Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data  Randomization to be Completed in Phase II Part in Q4 2025 2025 Half-Year Results and Business Update Positive Phase I data with TG4050 in operable Head and Neck Squamous Cell Carcinoma (HNSCC)  100% disease-free survival after 2 years of follow-up — data presented in a rapid oral presentation at ASCO (June 2025) Transgene to report additional immunological data at a scientific conference in Q4 2025 Ongoing Phase II part with TG4050 in operable HNSCC Patient screening comp...

 PRESS RELEASE

Mise à disposition du Rapport Financier Semestriel au 30 juin 2025

Mise à disposition du Rapport Financier Semestriel au 30 juin 2025 TRANSGENE (Paris : TNG) annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers le rapport semestriel au 30 juin 2025. Il peut être consulté sur le site internet de la société à l’adresse suivante : , dans la rubrique « Investisseurs – Informations financières ». Le rapport semestriel comprend les documents suivants : Information financière semestrielle 2025 ;Rapport semestriel d’activité ;Rapport des commissaires aux comptes sur l’information financière semestrielle 2025 ;Attes...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch